The long-term data supports the drug’s progression into the HEALEY ALS Platform trial, with NUZ-001 dosing set to commence in Q4 2025. This will only begin, however, if the US Food and Drug ...

Australia’s Neurizon Therapeutics, a biotech advancing innovative treatments for neurodegenerative diseases, has reported positive top-line results from the Open-Label Extension (OLE) study of its ...

Robin Leaper lost her voice to ALS. Artificial Intelligence has given her back the ability to speak with her own voice.

MTPA's oral therapy Radicava (edaravone) has shown decreased functional decline and improved survival in long-term ALS trials ...

Jodi O’Donnell-Ames founded Hope Loves Company to provide support, resources, and community to children affected by ALS.